This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market

Market Insights on Benign Prostatic Hyperplasia (BPH) Prostate Treatment covering sales outlook, demand forecast & up-to-date key trends

Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market By Treatment Type (BPH Drugs, BPH Devices), Distribution Channel (Institutional Sales, Retail Sales, Online Pharmacies) & Region - Forecast 2022 - 2028

Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market Outlook (2022-2028)

[252 Pages Report] Standing at a net worth of US$ 30.04 Bn in 2022, the global benign prostatic hyperplasia (BPH) prostate treatment market is anticipated to attain a valuation of US$ 39.5 Bn by the end of 2028. Demand for benign prostatic hyperplasia prostate treatment is projected to rise at a steady CAGR of 4.7% from 2022 to 22028.

Benign Prostatic Hyperplasia Prostate Treatment Market Size (2022)

US$ 30.04 Bn

Projected Market Value (2028)

US$ 39.5 Bn

Forecast Growth Rate (2022-2028)

4.7% CAGR

Dominant Distribution Channel

Institutional Sales - 64.7%

Worldwide benign prostatic hyperplasia treatment market revenue accounted for 23.8% share in the global cancer treatment market in 2021. Rising preference for minimally-invasive surgeries is anticipated to propel BPH surgical treatment procedure demand over the coming years.

Customize this Report

Let us know your requirement to get
100% FREE customization

How The Market Progressed Till June 2022?

Particulars

Details

H1, 2021

4.57%

H1, 2022 Projected

4.67%

H1, 2022 Outlook

4.17%

BPS Change - H1, 2022 (O) – H1, 2022 (P)

(-) 50 ↓

BPS Change – H1, 2022 (O) – H1, 2021

(-) 40 ↓

The variation between the BPS values observed within this market in H1, 2022 - outlook over H1, 2022 projected reflects a decline of 50 BPS units. A decline in BPS growth in H1-2022 over H1-2021 by 40 Basis Point Share (BPS) is demonstrated by the market.

The decline in the BPS values is associated with the emergence of urinary tract infections after treatment, increasing patient discomfort and raising healthcare costs, and the susceptibility to kidney damage.

However, with the advent of prostate artery embolization (PAE) procedures for the treatment of benign prostatic hyperplasia, the market is set to gain traction over the forecast period, owed to greater patient satisfaction rates and positive procedural outcomes.

The market is subject to changes as per the regulatory dynamics associated with the macro and industry standards. Key development in the market includes the launch of Optilume drug-coated balloon with enhanced efficacy for benign prostatic hyperplasia treatment.

Demand Analysis of BPH Prostate Treatment Drugs & Devices (2013 to 2021) Vs Future Market Metrics (2022 to 2028)

Increasing incidence of benign prostatic hyperplasia (BPH) is a major factor that is propelling demand for BPH treatment drugs and devices, and the trend has been picking up pace over the past few years. The global BPH prostate treatment market rose at a CAGR of 3.7% from 2013 to 2021.

Increasing focus on healthcare, rising geriatric population, deteriorating lifestyle, poor eating habits, hereditary inheritance of the disease, rising research and development, increasing availability of treatment procedures are some of the major factors influencing BPH treatment market growth.

Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market Download Report Brochure

However, side effects associated with BPH drugs are anticipated to have a restraining effect on the benign prostatic hyperplasia prostate treatment market potential.

High costs associated with BPH surgical treatment procedures are also expected to have a similar hindering effect. But, these factors are expected to favour demand for BPH homeopathy remedies, BPH relief medicine, and benign prostatic hyperplasia natural remedies over the forecast period.

The benign prostatic hyperplasia prostate treatment market is anticipated to expand at a CAGR of 4.7% from 2022 to 2028.

What’s Favouring BPH Treatment Market Potential?

“Rising Incidence of Benign Prostatic Hyperplasia”

Instances of benign prostatic hyperplasia have substantially risen and are expected to keep rising over the forecast period as well. The growing geriatric population across the world is a major factor that is governing the BPH treatment market potential.

BPH surgical treatment procedures are expected to see a rise as patient preference for minimally invasive surgeries increases.

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

What is the Outlook for BPH Drug Treatment?

“Rising Awareness about Side-Effects of BPH Drugs to Restrain Market Growth”

BPH drugs have been extensively used for benign prostatic hyperplasia treatment for quite a while now but now as the awareness for long-term side-effects of these drugs increases, their adoption is expected to see a drop and negatively affect the overall market growth.

BPH homeopathy remedies, benign prostatic hyperplasia home remedies, and benign prostatic hyperplasia natural remedies are expected to benefit from the aforementioned factor and are anticipated to see an increase in adoption from the growing patient pool across the world.

What is the Regional Outlook for the BPH Prostate Treatment Industry?

“North America to Hold Dominant Market Share through 2028”

This global BPH prostate treatment devices and drugs industry survey details market stance across regions such as North America, Latin America, Europe, East Asia, South Asia & Pacific, and the Middle East & Africa (MEA).

The North America BPH treatment market holds a dominant market share and is expected to maintain this outlook through 2028. Rising instances of benign prostatic hyperplasia, increasing geriatric population, and the presence of key benign prostatic hyperplasia prostate treatment providers are major factors influencing the market potential in this region.

The Europe BPH prostate treatment market is also expected to have a bright outlook over the forecast period. Increasing focus on healthcare and rising research activity in this region are expected to be major trends in the Europe BPH treatment industry through 2028.

East Asia and South Asia are expected to provide lucrative opportunities for BPH treatment over the forecast period. The rising geriatric population in India, China, and Japan is expected to be the most prominent trend in these regions and propel the demand for BHP treatment procedures. BHP drugs are expected to be more popular than BHP surgical treatment procedures in these regions.

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Country-wise Analysis

Why Should BPH Treatment Providers Focus on the U.S.?

“Rising Geriatric Population to Boost Demand for BPH Treatment Drugs & Devices”

The U.S. is anticipated to see a high demand for BPH treatment owing to the increasing incidence of benign prostatic hyperplasia. The nation is seeing a rise in its geriatric population which is more prone to this condition and hence is a highly lucrative market for BPH treatment providers.

Rising research and development activities and availability of BHT surgical treatment are also expected to influence market potential in the U.S.

What is the Outlook for BPH Treatment in India?

“Ayurveda Medicines for BPH Symptoms to See High Demand”

India is seeing a gradual increase in its geriatric population and this is expected to result in an increase in cases of benign prostatic hyperplasia. However, the popularity of Ayurveda in the nation is expected to propel sales of Ayurveda medicines for BPH symptoms, and also is expected to favor demand for benign prostatic hyperplasia natural remedies.

This will drive growth of BPH prostate treatment drug and device suppliers in the country.

Category-wise Analysis

Which Distribution Channel Holds a Dominant Market Outlook?

“High Institutional Sales of BPH Treatment Devices & Drugs”

Among all distribution channels, the institutional sales channel is expected to lead the market and currently accounts for a major market share of 64.7% in the global benign prostatic hyperplasia prostate treatment space. Increasing number of minimally invasive surgeries performed in hospitals and specialty clinics are expected to boost institutional sales segment market share through 2028.

Meanwhile, BPH prostate treatment drug retail sales and online pharmacies segments hold market shares of 26.7% and 8.6%, respectively, in the global BPH treatment industry at present.

COVID-19 Crisis Survey

Sudden emergence of the COVID-19 pandemic took the world by shock and had an adverse impact on all healthcare procedures and treatments, as lack of resources during the pandemic didn’t allow healthcare facilities to focus on these treatments.

Facilities were overloaded with high cases of COVID-19 infections across the world and BPH prostate treatment procedures were overlooked which resulted in a negative trend for benign prostatic hyperplasia (BPH) prostate treatment market.

However, BPH homeopathy remedies, BPH relief medicines, benign prostatic hyperplasia over-the-counter medication, and other alternate treatments saw good growth in demand in the pandemic era.

The BPH treatment systems market is anticipated to make a steady comeback in the post-pandemic era as the coronavirus infection load from healthcare facilities is lessened and they can focus on the treatment of other conditions as well.

Benign prostatic hyperplasia natural remedies are expected to see a substantial rise in popularity in the post-pandemic era as awareness about over-the-counter BPH medication side effects increases.

Competitive Landscape

BPH prostate treatment device and drug manufacturers are investing in research & development to come up with novel treatments to offer better treatment opportunities for people suffering from the disease.

  • In March 2022, ProVerum, an Irish medtech firm, announced that it had raised around US$ 33 Mn for the clinical trials of its novel treatment for benign prostatic hyperplasia, which is a common condition in aging men.

BPH Prostate Treatment Industry Report Scope

Attribute

Details

Forecast Period

2022-2028

Historical Data Available for

2013-2021

Market Analysis

US$ Mn for Value

Key Regions Covered

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia & Pacific
  • Middle East & Africa (MEA)

Key Counties Covered

  • United States
  • Canada
  • Brazil
  • Mexico
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • China
  • Japan
  • South Korea
  • India
  • Indonesia
  • Malaysia
  • Singapore
  • Australia
  • New Zealand
  • Turkey
  • South Africa
  • and GCC Countries

Key Market Segments Covered

  • Treatment Type
  • Distribution Channel
  • Region

Key Companies Profiled

  • Pfizer Inc.
  • NxThera Inc.
  • NeoTract Inc.
  • Sanofi S.A
  • GlaxoSmithKline Plc.
  • Allergan Plc.
  • Teva Pharmaceutical Industries Ltd.
  • Mylan N.V.
  • Eli Lily & Company
  • Cardinal Health Inc.

Pricing

Available upon Request

Key Segments of BPH Prostate Treatment Industry Survey

BPH Prostate Treatment Market by Treatment Type:

  • BPH Drugs
    • Alpha Blockers
    • 5-Aplha Reductase Inhibitors
    • Phosphodiesterase-5 (PDE-5) Inhibitors
    • Muscarinic Receptor Antagonist (MRA)
    • Combination Drug
  • BPH Devices
    • Prostatic Stents
    • Suture Base Implant Systems
    • Transurethral RF Thermal Therapy Devices

BPH Prostate Treatment Market by Distribution Channel:

  • Institutional Sales
    • Hospitals
    • Ambulatory Surgical Centres
    • Specialty Clinics
  • Retail Sales
    • Retail Pharmacies
    • Drug Stores
  • Online Pharmacies

BPH Prostate Treatment Market by Region:

  • North America BPH Prostate Treatment Market
  • Latin America BPH Prostate Treatment Market
  • Europe BPH Prostate Treatment Market
  • East Asia BPH Prostate Treatment Market
  • South Asia & Pacific BPH Prostate Treatment Market
  • Middle East & Africa (MEA) BPH Prostate Treatment Market

Frequently Asked Questions

In 2022, the global benign prostatic hyperplasia (BPH) prostate treatment market stands at a net worth of US$ 30.04 Bn.

The BPH prostate treatment market is predicted to attain a valuation of US$ 39.5 Bn by 2028.

Institutional sales account for a dominant market share of 64.7% in 2022.

Key market players are Pfizer Inc., NxThera Inc., NeoTract Inc., Sanofi S.A, GlaxoSmithKline Plc., and Allergan Plc.

From 2022 to 2028, the benign prostatic hyperplasia prostate treatment industry is estimated to evolve at a CAGR of 4.7%.

Table of Content

1. Executive Summary

     1.1. Market Overview

     1.2. Market Analysis

     1.3. Technology Roadmap

     1.4. FMI Analysis and Recommendations

2. Market Introduction

     2.1. Market Introduction

     2.2. Market Taxonomy

     2.3. Market Definition

     2.4. Inclusions and Exclusions

3. Benign Prostatic Hyperplasia Prostate Treatment Market Opportunity Analysis 

     3.1. Macro-Economic Factors

     3.2. Opportunity Analysis

4. Market Background

     4.1. Market Dynamics

           4.1.1. Drivers

           4.1.2. Restraints

           4.1.3. Key Trends

5. Key Inclusions

     5.1. Pipeline Analysis

     5.2. Prevalence and Treatment Seeking Population Analysis

6. Global Economic Outlook

     6.1. Gross Domestic Product by Region & Country, 2006 – 2021

7. Global Benign Prostatic Hyperplasia Prostate Treatment Market Analysis 2013–2021 and Forecast 2022–2028, By Region

     7.1. Introduction / Key Findings

     7.2. Historical Market Size (US$ Mn) Trend Analysis by Region, 2013–2021

           7.2.1. North America

           7.2.2. Latin America

           7.2.3. Europe

           7.2.4. South Asia

           7.2.5. East Asia

           7.2.6. Oceania

           7.2.7. The Middle East and Africa

           7.2.8. Emerging Countries

     7.3. Market Size (US$ Mn) Forecast By Region, 2022–2028

     7.4. Market Attractiveness Analysis by Region

8. Global Benign Prostatic Hyperplasia Prostate Treatment Market Analysis 2013–2021 and Forecast 2022–2028, By Treatment Type

     8.1. Introduction

     8.2. Historical Market Size (US$ Mn) Trend Analysis by Treatment Type, 2013–2021

           8.2.1. Drugs

                    8.2.1.1. Alpha Blockers

                    8.2.1.2. 5-alpha Reductase Inhibitors

                    8.2.1.3. Phosphodiesterase-5 (PDE-5) Inhibitors

                    8.2.1.4. Muscarinic Receptor Antagonist (MRA)

                    8.2.1.5. Combination Drug

           8.2.2. Device

                    8.2.2.1. Prostatic Stents

                    8.2.2.2. Suture Base Implant Systems

                    8.2.2.3. Transurethral RF Thermal Therapy Devices

     8.3. Market Size (US$ Mn) Forecast By Treatment Type, 2022–2028

     8.4. Market Attractiveness Analysis by Treatment Type

9. Global Benign Prostatic Hyperplasia Prostate Treatment Market Analysis 2013–2021 and Forecast 2022–2028, By Distribution Channels

     9.1. Introduction

     9.2. Historical Market Size (US$ Mn) Trend Analysis by Distribution Channels, 2013–2021

           9.2.1. Institutional Sales

                    9.2.1.1. Hospital

                    9.2.1.2. Ambulatory Surgical Centers

                    9.2.1.3. Specialty Clinics

           9.2.2. Retail Sales

                    9.2.2.1. Retail Pharmacies

                    9.2.2.2. Drug Stores

           9.2.3. Online Pharmacies

     9.3. Market Size (US$ Mn) Forecast By Distribution Channels, 2022–2028

     9.4. Market Attractiveness Analysis by Distribution Channels

10. North America Benign Prostatic Hyperplasia Prostate Treatment Market Analysis 2013–2021 and Forecast 2022–2028

     10.1. Introduction

     10.2. Historical Market Size (US$ Mn) Analysis by Country, 2013–2021

           10.2.1. U.S.

           10.2.2. Canada

     10.3. Market Size (US$ Mn) Forecast By Country, 2022–2028

     10.4. Historical Market Size (US$ Mn) Trend Analysis by Treatment Type, 2013–2021

           10.4.1. Drugs

                    10.4.1.1. Alpha Blockers

                    10.4.1.2. 5-alpha Reductase Inhibitors

                    10.4.1.3. Phosphodiesterase-5 (PDE-5) Inhibitors

                    10.4.1.4. Muscarinic Receptor Antagonist (MRA)

                    10.4.1.5. Combination Drug

           10.4.2. Device

                    10.4.2.1. Prostatic Stents

                    10.4.2.2. Suture Base Implant Systems

                    10.4.2.3. Transurethral RF Thermal Therapy Devices

     10.5. Market Size (US$ Mn) Forecast By Treatment Type, 2022–2028

     10.6. Historical Market Size (US$ Mn) Trend Analysis by Distribution Channels, 2013–2021

           10.6.1. Institutional Sales

                    10.6.1.1. Hospital

                    10.6.1.2. Ambulatory Surgical Centers

                    10.6.1.3. Specialty Clinics

           10.6.2. Retail Sales

                    10.6.2.1. Retail Pharmacies

                    10.6.2.2. Drug Stores

           10.6.3. Online Pharmacies

     10.7. Market Size (US$ Mn) Forecast By Distribution Channels, 2022–2028

     10.8. Market Attractiveness Analysis

           10.8.1. By Country

           10.8.2. By Treatment Type

           10.8.3. By Distribution Channel

     10.9. Market Size and Forecast Factors

     10.10. Key Intensity Mapping

11. Latin America Benign Prostatic Hyperplasia Prostate Treatment Market Analysis 2013–2021 and Forecast 2022–2028

     11.1. Introduction

     11.2. Historical Market Size (US$ Mn) By Country, 2013–2021

           11.2.1. Brazil

           11.2.2. Mexico

           11.2.3. Rest of Latin America

     11.3. Market Size (US$ Mn) Forecast By Country, 2022–2028

     11.4. Historical Market Size (US$ Mn) Trend Analysis by Treatment Type, 2013–2021

           11.4.1. Drugs

                    11.4.1.1. Alpha Blockers

                    11.4.1.2. 5-alpha Reductase Inhibitors

                    11.4.1.3. Phosphodiesterase-5 (PDE-5) Inhibitors

                    11.4.1.4. Muscarinic Receptor Antagonist (MRA)

                    11.4.1.5. Combination Drug

           11.4.2. Device

                    11.4.2.1. Prostatic Stents

                    11.4.2.2. Suture Base Implant Systems

                    11.4.2.3. Transurethral RF Thermal Therapy Devices

     11.5. Market Size (US$ Mn) Forecast By Treatment Type, 2022–2028

     11.6. Historical Market Size (US$ Mn) Trend Analysis by Distribution Channels, 2013–2021

           11.6.1. Institutional Sales

                    11.6.1.1. Hospital

                    11.6.1.2. Ambulatory Surgical Centers

                    11.6.1.3. Specialty Clinics

           11.6.2. Retail Sales

                    11.6.2.1. Retail Pharmacies

                    11.6.2.2. Drug Stores

           11.6.3. Online Pharmacies

     11.7. Market Size (US$ Mn) Forecast By Distribution Channels, 2022–2028

     11.8. Market Attractiveness Analysis

           11.8.1. By Country

           11.8.2. By Treatment Type

           11.8.3. By Distribution Channel

     11.9. Market Size and Forecast Factors

     11.10. Key Intensity Mapping

12. Europe Benign Prostatic Hyperplasia Prostate Treatment Market Analysis 2013–2021 and Forecast 2022–2028

     12.1. Introduction

     12.2. Historical Market Size (US$ Mn) Analysis by Country, 2013–2021

           12.2.1. Germany

           12.2.2. U.K.

           12.2.3. France

           12.2.4. Italy

           12.2.5. Russia

           12.2.6. Spain

           12.2.7. Rest of Europe

     12.3. Market Size (US$ Mn) Forecast By Country, 2022–2028

     12.4. Historical Market Size (US$ Mn) Trend Analysis by Treatment Type, 2013–2021

           12.4.1. Drugs

                    12.4.1.1. Alpha Blockers

                    12.4.1.2. 5-alpha Reductase Inhibitors

                    12.4.1.3. Phosphodiesterase-5 (PDE-5) Inhibitors

                    12.4.1.4. Muscarinic Receptor Antagonist (MRA)

                    12.4.1.5. Combination Drug

           12.4.2. Device

                    12.4.2.1. Prostatic Stents

                    12.4.2.2. Suture Base Implant Systems

                    12.4.2.3. Transurethral RF Thermal Therapy Devices

     12.5. Market Size (US$ Mn) Forecast By Treatment Type, 2022–2028

     12.6. Historical Market Size (US$ Mn) Trend Analysis by Distribution Channels, 2013–2021

           12.6.1. Institutional Sales

                    12.6.1.1. Hospital

                    12.6.1.2. Ambulatory Surgical Centers

                    12.6.1.3. Specialty Clinics

           12.6.2. Retail Sales

                    12.6.2.1. Retail Pharmacies

                    12.6.2.2. Drug Stores

           12.6.3. Online Pharmacies

     12.7. Market Size (US$ Mn) Forecast By Distribution Channels, 2022–2028

     12.8. Market Attractiveness Analysis

           12.8.1. By Country

           12.8.2. By Treatment Type

           12.8.3. By Distribution Channel

     12.9. Market Size and Forecast Factors

     12.10. Key Intensity Mapping

13. South Asia Benign Prostatic Hyperplasia Prostate Treatment Analysis 2013–2021 and Forecast 2022–2028

     13.1. Introduction

     13.2. Historical Market Size (US$ Mn) By Country, 2013–2021

           13.2.1. India

           13.2.2. Thailand

           13.2.3. Indonesia

           13.2.4. Malaysia

           13.2.5. Rest of South Asia

     13.3. Market Size (US$ Mn) Forecast By Country, 2022–2028

     13.4. Historical Market Size (US$ Mn) Trend Analysis by Treatment Type, 2013–2021

           13.4.1. Drugs

                    13.4.1.1. Alpha Blockers

                    13.4.1.2. 5-alpha Reductase Inhibitors

                    13.4.1.3. Phosphodiesterase-5 (PDE-5) Inhibitors

                    13.4.1.4. Muscarinic Receptor Antagonist (MRA)

                    13.4.1.5. Combination Drug

           13.4.2. Device

                    13.4.2.1. Prostatic Stents

                    13.4.2.2. Suture Base Implant Systems

               13.4.2.3. Transurethral RF Thermal Therapy Devices

     13.5. Market Size (US$ Mn) Forecast By Treatment Type, 2022–2028

     13.6. Historical Market Size (US$ Mn) Trend Analysis by Distribution Channels, 2013–2021

           13.6.1. Institutional Sales

                    13.6.1.1. Hospital

                    13.6.1.2. Ambulatory Surgical Centers

                    13.6.1.3. Specialty Clinics

           13.6.2. Retail Sales

                    13.6.2.1. Retail Pharmacies

                    13.6.2.2. Drug Stores

13.6.3. Online Pharmacies

     13.7. Market Size (US$ Mn) Forecast By Distribution Channels, 2022–2028

     13.8. Market Attractiveness Analysis

           13.8.1. By Country

           13.8.2. By Treatment Type

           13.8.3. By Distribution Channel

     13.9. Market Size and Forecast Factors

     13.10. Key Intensity Mapping

14. East Asia Benign Prostatic Hyperplasia Prostate Treatment Market Analysis 2013–2021 and Forecast 2022–2028

     14.1. Introduction

     14.2. Historical Market Size (US$ Mn) By Country, 2013–2021

           14.2.1. China

           14.2.2. Japan

           14.2.3. South Korea

     14.3. Market Size (US$ Mn) Forecast By Country, 2022–2028

     14.4. Historical Market Size (US$ Mn) Trend Analysis by Treatment Type, 2013–2021

           14.4.1. Drugs

                    14.4.1.1. Alpha Blockers

                    14.4.1.2. 5-alpha Reductase Inhibitors

                    14.4.1.3. Phosphodiesterase-5 (PDE-5) Inhibitors

                    14.4.1.4. Muscarinic Receptor Antagonist (MRA)

                    14.4.1.5. Combination Drug

           14.4.2. Device

                    14.4.2.1. Prostatic Stents

                    14.4.2.2. Suture Base Implant Systems

                    14.4.2.3. Transurethral RF Thermal Therapy Devices

     14.5. Market Size (US$ Mn) Forecast By Treatment Type, 2022–2028

     14.6. Historical Market Size (US$ Mn) Trend Analysis by Distribution Channels, 2013–2021

           14.6.1. Institutional Sales

                    14.6.1.1. Hospital

                    14.6.1.2. Ambulatory Surgical Centers

                    14.6.1.3. Specialty Clinics

           14.6.2. Retail Sales

                    14.6.2.1. Retail Pharmacies

                    14.6.2.2. Drug Stores

           14.6.3. Online Pharmacies

     14.7. Market Size (US$ Mn) Forecast By Distribution Channels, 2022–2028

     14.8. Market Attractiveness Analysis

           14.8.1. By Country

           14.8.2. By Treatment Type

           14.8.3. By Distribution Channel

     14.9. Market Size and Forecast Factors

     14.10. Key Intensity Mapping

15. Oceania Benign Prostatic Hyperplasia Prostate Treatment Market Analysis 2013–2021 and Forecast 2022–2028

     15.1. Introduction

     15.2. Historical Market Size (US$ Mn) By Country, 2013–2021

           15.2.1. Australia

           15.2.2. New Zealand

     15.3. Market Size (US$ Mn) Forecast By Country, 2022–2028

     15.4. Historical Market Size (US$ Mn) Trend Analysis By Treatment Type, 2013–2021

           15.4.1. Drugs

                    15.4.1.1. Alpha Blockers

                    15.4.1.2. 5-alpha Reductase Inhibitors

                    15.4.1.3. Phosphodiesterase-5 (PDE-5) Inhibitors

                    15.4.1.4. Muscarinic Receptor Antagonist (MRA)

                    15.4.1.5. Combination Drug

           15.4.2. Device

                    15.4.2.1. Prostatic Stents

                    15.4.2.2. Suture Base Implant Systems

                    15.4.2.3. Transurethral RF Thermal Therapy Devices

     15.5. Market Size (US$ Mn)  Forecast By Treatment Type, 2022–2028

     15.6. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channels, 2013–2021

           15.6.1. Institutional Sales

                    15.6.1.1. Hospital

                    15.6.1.2. Ambulatory Surgical Centers

                    15.6.1.3. Specialty Clinics

           15.6.2. Retail Sales

                    15.6.2.1. Retail Pharmacies

                    15.6.2.2. Drug Stores

           15.6.3. Online Pharmacies

     15.7. Market Size (US$ Mn) Forecast By Distribution Channels, 2022–2028

     15.8. Market Attractiveness Analysis

           15.8.1. By Country

           15.8.2. By Treatment Type

           15.8.3. By Distribution Channel

     15.9. Market Size and Forecast Factors

     15.10. Key Intensity Mapping

16. MEA Benign Prostatic Hyperplasia Prostate Treatment Market Analysis 2013–2021 and Forecast 2022–2028

     16.1. Introduction

     16.2. Historical Market Size (US$ Mn) By Country, 2013–2021

           16.2.1. GCC Countries

           16.2.2. Turkey

           16.2.3. South Africa

           16.2.4. North Africa

           16.2.5. Rest of MEA

     16.3. Market Size (US$ Mn) Forecast By Country, 2022–2028

     16.4. Historical Market Size (US$ Mn) Trend Analysis By Treatment Type, 2013–2021

           16.4.1. Drugs

                    16.4.1.1. Alpha Blockers

                    16.4.1.2. 5-alpha Reductase Inhibitors

                    16.4.1.3. Phosphodiesterase-5 (PDE-5) Inhibitors

                    16.4.1.4. Muscarinic Receptor Antagonist (MRA)

                    16.4.1.5. Combination Drug

           16.4.2. Device

                    16.4.2.1. Prostatic Stents

                    16.4.2.2. Suture Base Implant Systems

                    16.4.2.3. Transurethral RF Thermal Therapy Devices

     16.5. Market Size (US$ Mn)  Forecast By Treatment Type, 2022–2028

     16.6. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channels, 2013–2021

           16.6.1. Institutional Sales

                    16.6.1.1. Hospital

                    16.6.1.2. Ambulatory Surgical Centers

                    16.6.1.3. Specialty Clinics

           16.6.2. Retail Sales

                    16.6.2.1. Retail Pharmacies

                    16.6.2.2. Drug Stores

           16.6.3. Online Pharmacies

     16.7. Market Size (US$ Mn) Forecast By Distribution Channels, 2022–2028

     16.8. Market Attractiveness Analysis

           16.8.1. By Country

           16.8.2. By Treatment Type

           16.8.3. By Distribution Channel

     16.9. Market Size and Forecast Factors

     16.10. Key Intensity Mapping

17. Emerging Countries Benign Prostatic Hyperplasia Prostate Treatment Market Analysis 2013–2021 and Forecast 2022–2028

     17.1. Introduction

     17.2. Historical Market Size (US$ Mn) By Country, 2013–2021

           17.2.1. China

           17.2.2. Brazil

           17.2.3. South Africa

     17.3. Market Size (US$ Mn) Forecast By Country, 2022–2028

     17.4. Historical Market Size (US$ Mn) Trend Analysis By Treatment Type, 2013–2021

           17.4.1. Drugs

                    17.4.1.1. Alpha Blockers

                    17.4.1.2. 5-alpha Reductase Inhibitors

                    17.4.1.3. Phosphodiesterase-5 (PDE-5) Inhibitors

                    17.4.1.4. Muscarinic Receptor Antagonist (MRA)

                    17.4.1.5. Combination Drug

           17.4.2. Device

                    17.4.2.1. Prostatic Stents

                    17.4.2.2. Suture Base Implant Systems

                    17.4.2.3. Transurethral RF Thermal Therapy Devices

     17.5. Market Size (US$ Mn) Forecast By Treatment Type, 2022–2028

     17.6. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channels, 2013–2021

           17.6.1. Institutional Sales

                    17.6.1.1. Hospital

                    17.6.1.2. Ambulatory Surgical Centers

                    17.6.1.3. Specialty Clinics

           17.6.2. Retail Sales

                    17.6.2.1. Retail Pharmacies

                    17.6.2.2. Drug Stores

           17.6.3. Online Pharmacies

     17.7. Market Size (US$ Mn) Forecast By Distribution Channels, 2022–2028

     17.8. Market Attractiveness Analysis

           17.8.1. By Country

           17.8.2. By Treatment Type

           17.8.3. By Distribution Channel

     17.9. Market Size and Forecast Factors

     17.10. Key Intensity Mapping

18. Competitive Landscape

     18.1. Competition Dashboard

     18.2. Company Deep Dive

           18.2.1. Pfizer, Inc.

                    18.2.1.1. Company Overview

                    18.2.1.2. Product Portfolio

                    18.2.1.3. Key Financials and Y-O-Y Growth

                    18.2.1.4. Key Development and Strategy

           18.2.2. NxThera Inc.

                    18.2.2.1. Company Overview

                    18.2.2.2. Product Portfolio

                    18.2.2.3. Key Financials and Y-O-Y Growth

                    18.2.2.4. Key Development and Strategy

           18.2.3. NeoTract, Inc.

                    18.2.3.1. Company Overview

                    18.2.3.2. Product Portfolio

                    18.2.3.3. Key Financials and Y-O-Y Growth

                    18.2.3.4. Key Development and Strategy

           18.2.4. Sanofi S.A.

                    18.2.4.1. Company Overview

                    18.2.4.2. Product Portfolio

                    18.2.4.3. Key Financials and Y-O-Y Growth

                    18.2.4.4. Key Development and Strategy

           18.2.5. GlaxoSmithKline plc.

                    18.2.5.1. Company Overview

                    18.2.5.2. Product Portfolio

                    18.2.5.3. Key Financials and Y-O-Y Growth

                    18.2.5.4. Key Development and Strategy

           18.2.6. Allergan plc.

                    18.2.6.1. Company Overview

                    18.2.6.2. Product Portfolio

                    18.2.6.3. Key Financials and Y-O-Y Growth

                    18.2.6.4. Key Development and Strategy

           18.2.7. Teva Pharmaceutical Industries Ltd

                    18.2.7.1. Company Overview

                    18.2.7.2. Product Portfolio

                    18.2.7.3. Key Financials and Y-O-Y Growth

                    18.2.7.4. Key Development and Strategy

           18.2.8. Mylan N.V.

                    18.2.8.1. Company Overview

                    18.2.8.2. Product Portfolio

                    18.2.8.3. Key Financials and Y-O-Y Growth

                    18.2.8.4. Key Development and Strategy

           18.2.9. Eli Lilly and Company

                    18.2.9.1. Company Overview

                    18.2.9.2. Product Portfolio

                    18.2.9.3. Key Financials and Y-O-Y Growth

                    18.2.9.4. Key Development and Strategy

           18.2.10. Cardinal Health Inc.

                    18.2.10.1. Company Overview

                    18.2.10.2. Product Portfolio

                    18.2.10.3. Key Financials and Y-O-Y Growth

                    18.2.10.4. Key Development and Strategy

19. Assumptions and Acronyms Used 

20. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 1: Expenditure on Health (% of GDP) by Country, 2016-2021

Table 2: Expenditure on Health (% of GDP) by Country, 2016-2021

Table 3: Global Benign Prostatic Hyperplasia Prostate Treatment Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Region

Table 4: Global Benign Prostatic Hyperplasia Prostate Treatment Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Treatment

Table 5: Global Benign Prostatic Hyperplasia Prostate Treatment Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Distribution Channel

Table 6: North America Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Country

Table 7: North America Benign Prostatic Hyperplasia Prostate Treatment Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Treatment

Table 8: North America Benign Prostatic Hyperplasia Prostate Treatment Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Distribution Channel

Table 9: Latin America Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Country

Table 10: Latin America Benign Prostatic Hyperplasia Prostate Treatment Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Treatment

Table 11: Latin America Benign Prostatic Hyperplasia Prostate Treatment Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Distribution Channel

Table 12: Europe Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Country

Table 13: Europe Benign Prostatic Hyperplasia Prostate Treatment Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Treatment

Table 14: Europe Benign Prostatic Hyperplasia Prostate Treatment Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Distribution Channel

Table 15: South Asia Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Country

Table 16: South Asia Benign Prostatic Hyperplasia Prostate Treatment Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Treatment

Table 17: South Asia Benign Prostatic Hyperplasia Prostate Treatment Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Distribution Channel

Table 18: East Asia Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Country

Table 19: East Asia Benign Prostatic Hyperplasia Prostate Treatment Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Treatment

Table 20: East Asia Benign Prostatic Hyperplasia Prostate Treatment Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Distribution Channel

Table 21: Oceania Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Country

Table 22: Oceania Benign Prostatic Hyperplasia Prostate Treatment Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Treatment

Table 23: Oceania Benign Prostatic Hyperplasia Prostate Treatment Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Distribution Channel

Table 24: Middle-East & Africa Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Country

Table 25: Middle-East & Africa Benign Prostatic Hyperplasia Prostate Treatment Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Treatment

Table 26: Middle-East & Africa Benign Prostatic Hyperplasia Prostate Treatment Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Distribution Channel

Table 27: China Benign Prostatic Hyperplasia Prostate Treatment Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Treatment

Table 28: China Benign Prostatic Hyperplasia Prostate Treatment Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Distribution Channel

Table 29: Brazil Benign Prostatic Hyperplasia Prostate Treatment Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Treatment

Table 30: Brazil Benign Prostatic Hyperplasia Prostate Treatment Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Distribution Channel

Table 31: South Africa Benign Prostatic Hyperplasia Prostate Treatment Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Treatment

Table 32: South Africa Benign Prostatic Hyperplasia Prostate Treatment Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Distribution Channel

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 1: Global Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Treatment, 2021A

Figure 2: Global Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Drugs, 2021A

Figure 3: Global Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Devices, 2021A

Figure 4: Global Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Distribution Channel, 2021A

Figure 5: Global Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Institutional Sales, 2021A

Figure 6: Global Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Retail Sales, 2021A

Figure 7a: World GDP (Nominal) by Selected Economies, 2021

Figure 7b: Global Healthcare Expenditure in US$ Bn (2013–2020)

Figure 8: Global Benign Prostatic Hyperplasia Prostate Treatment Market Value (US$ Mn), By Region, 2022E & 2028F

Figure 9: Global Benign Prostatic Hyperplasia Prostate Treatment Market Attractiveness Analysis, By Region, 2022E

Figure 10: Global Benign Prostatic Hyperplasia Prostate Treatment Market Value (US$ Mn), By Treatment, 2022E & 2028F

Figure 11: Global Benign Prostatic Hyperplasia Prostate Treatment Market Attractiveness Analysis, By Treatment, 2022E

Figure 12: Global Benign Prostatic Hyperplasia Prostate Treatment Market Value (US$ Mn), By Distribution Channel, 2022E & 2028F

Figure 13: Global Benign Prostatic Hyperplasia Prostate Treatment Market Attractiveness Analysis, By Distribution Channel, 2022E

Figure 14: North America Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Treatment, 2021A

Figure 15: North America Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Drugs, 2021A

Figure 16: North America Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Devices, 2021A

Figure 17: North America Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Distribution Channel, 2021A

Figure 18: North America Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Institutional Sales, 2021A

Figure 19: North America Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Retail Sales, 2021A

Figure 019: Brazil Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) & Y-o-Y Growth (%), 2022–2028

Figure 20: North America Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) Analysis, 2013–2021

Figure 21: North America Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) & Y-o-Y Growth (%), 2022–2028

Figure 22: North America Benign Prostatic Hyperplasia Prostate Treatments Market Attractiveness Analysis, By Country, 2022E

Figure 23: North America Benign Prostatic Hyperplasia Prostate Treatment Market Attractiveness Analysis, By Treatment, 2022E

Figure 24: North America Benign Prostatic Hyperplasia Prostate Treatment Market Attractiveness Analysis, By Distribution Channel, 2022E

Figure 25: Latin America Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Treatment, 2021A

Figure 26: Latin America Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Drugs, 2021A

Figure 27: Latin America Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Devices, 2021A

Figure 28: Latin America Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Distribution Channel, 2021A

Figure 29: Latin America Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Institutional Sales, 2021A

Figure 30: Latin America Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Retail Sales, 2021A

Figure 31: Latin America Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) Analysis, 2013–2021

Figure 32: Latin America Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) & Y-o-Y Growth (%), 2022–2028

Figure 33: Latin America Benign Prostatic Hyperplasia Prostate Treatments Market Attractiveness Analysis, By Country, 2022E

Figure 34: Latin America Benign Prostatic Hyperplasia Prostate Treatment Market Attractiveness Analysis, By Treatment, 2022E

Figure 35: Latin America Benign Prostatic Hyperplasia Prostate Treatment Market Attractiveness Analysis, By Distribution Channel, 2022E

Figure 36: Europe Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Treatment, 2021A

Figure 37: Europe Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Drugs, 2021A

Figure 38: Europe Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Devices, 2021A

Figure 39: Europe Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Distribution Channel, 2021A

Figure 40: Europe Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Institutional Sales, 2021A

Figure 41: Europe Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Retail Sales, 2021A

Figure 42: Europe Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) Analysis, 2013–2021

Figure 43: Europe Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) & Y-o-Y Growth (%), 2022–2028

Figure 44: Europe Benign Prostatic Hyperplasia Prostate Treatments Market Attractiveness Analysis, By Country, 2022E

Figure 45: Europe Benign Prostatic Hyperplasia Prostate Treatment Market Attractiveness Analysis, By Treatment, 2022E

Figure 46: Europe Benign Prostatic Hyperplasia Prostate Treatment Market Attractiveness Analysis, By Distribution Channel, 2022E

Figure 47: South Asia Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Treatment, 2021A

Figure 48: South Asia Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Drugs, 2021A

Figure 49: South Asia Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Devices, 2021A

Figure 50: South Asia Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Distribution Channel, 2021A

Figure 51: South Asia Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Institutional Sales, 2021A

Figure 52: South Asia Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Retail Sales, 2021A

Figure 53: South Asia Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) Analysis, 2013–2021

Figure 54: South Asia Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) & Y-o-Y Growth (%), 2022–2028

Figure 55: South Asia Benign Prostatic Hyperplasia Prostate Treatments Market Attractiveness Analysis, By Country, 2022E

Figure 56: South Asia Benign Prostatic Hyperplasia Prostate Treatment Market Attractiveness Analysis, By Treatment, 2022E

Figure 57: South Asia Benign Prostatic Hyperplasia Prostate Treatment Market Attractiveness Analysis, By Distribution Channel, 2022E

Figure 58: East Asia Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Treatment, 2021A

Figure 59: East Asia Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Drugs, 2021A

Figure 60: East Asia Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Devices, 2021A

Figure 61: East Asia Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Distribution Channel, 2021A

Figure 62: East Asia Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Institutional Sales, 2021A

Figure 63: East Asia Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Retail Sales, 2021A

Figure 64: East Asia Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) Analysis, 2013–2021

Figure 65: East Asia Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) & Y-o-Y Growth (%), 2022–2028

Figure 66: East Asia Benign Prostatic Hyperplasia Prostate Treatments Market Attractiveness Analysis, By Country, 2022E

Figure 67: East Asia Benign Prostatic Hyperplasia Prostate Treatment Market Attractiveness Analysis, By Treatment, 2022E

Figure 68: East Asia Benign Prostatic Hyperplasia Prostate Treatment Market Attractiveness Analysis, By Distribution Channel, 2022E

Figure 69: Oceania Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Treatment, 2021A

Figure 70: Oceania Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Drugs, 2021A

Figure 71: Oceania Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Devices, 2021A

Figure 72: Oceania Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Distribution Channel, 2021A

Figure 73: Oceania Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Institutional Sales, 2021A

Figure 74: Oceania Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Retail Sales, 2021A

Figure 75: Oceania Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) Analysis, 2013–2021

Figure 76: Oceania Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) & Y-o-Y Growth (%), 2022–2028

Figure 77: Oceania Benign Prostatic Hyperplasia Prostate Treatments Market Attractiveness Analysis, By Country, 2022E

Figure 78: Oceania Benign Prostatic Hyperplasia Prostate Treatment Market Attractiveness Analysis, By Treatment, 2022E

Figure 79: Oceania Benign Prostatic Hyperplasia Prostate Treatment Market Attractiveness Analysis, By Distribution Channel, 2022E

Figure 80: Middle-East & Africa Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Treatment, 2021A

Figure 81: Middle-East & Africa Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Drugs, 2021A

Figure 82: Middle-East & Africa Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Devices, 2021A

Figure 83: Middle-East & Africa Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Distribution Channel, 2021A

Figure 84: Middle-East & Africa Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Institutional Sales, 2021A

Figure 85: Middle-East & Africa Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Retail Sales, 2021A

Figure 86: Middle-East & Africa Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) Analysis, 2013–2021

Figure 87: Middle-East & Africa Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) & Y-o-Y Growth (%), 2022–2028

Figure 88: Middle-East & Africa Benign Prostatic Hyperplasia Prostate Treatments Market Attractiveness Analysis, By Country, 2022E

Figure 89: Middle-East & Africa Benign Prostatic Hyperplasia Prostate Treatment Market Attractiveness Analysis, By Treatment, 2022E

Figure 90: Middle-East & Africa Benign Prostatic Hyperplasia Prostate Treatment Market Attractiveness Analysis, By Distribution Channel, 2022E

Figure 91: Emerging Countries Benign Prostatic Hyperplasia Prostate Treatment Market Value Share (2021A)

Figure 92: Emerging Countries Benign Prostatic Hyperplasia Prostate Treatment Market Value (US$ Mn), By Key Countries, 2021A-2028E

Figure 93: China Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Treatment, 2021A

Figure 94: China Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Drugs, 2021A

Figure 95: China Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Devices, 2021A

Figure 96: China Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Distribution Channel, 2021A

Figure 97: China Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Institutional Sales, 2021A

Figure 98: China Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Retail Sales, 2021A

Figure 99: China Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) Analysis, 2013–2021

Figure 100: China Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) & Y-o-Y Growth (%), 2022–2028

Figure 101: China Benign Prostatic Hyperplasia Prostate Treatment Market Attractiveness Analysis, By Treatment, 2022E

Figure 102: China Benign Prostatic Hyperplasia Prostate Treatment Market Attractiveness Analysis, By Distribution Channel, 2022E

Figure 103: Brazil Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Treatment, 2021A

Figure 104: Brazil Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Drugs, 2021A

Figure 105: Brazil Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Devices, 2021A

Figure 105: Brazil Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Distribution Channel, 2021A

Figure 106: Brazil Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Institutional Sales, 2021A

Figure 107: Brazil Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Retail Sales, 2021A

Figure 108: Brazil Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) Analysis, 2013–2021

Figure 110: Brazil Benign Prostatic Hyperplasia Prostate Treatment Market Attractiveness Analysis, By Treatment, 2022E

Figure 111: Brazil Benign Prostatic Hyperplasia Prostate Treatment Market Attractiveness Analysis, By Distribution Channel, 2022E

Figure 112: South Africa Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Treatment, 2021A

Figure 113: South Africa Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Drugs, 2021A

Figure 114: South Africa Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Devices, 2021A

Figure 115: South Africa Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Distribution Channel, 2021A

Figure 116: South Africa Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Institutional Sales, 2021A

Figure 117: South Africa Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Retail Sales, 2021A

Figure 118: South Africa Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) Analysis, 2013–2021

Figure 119: South Africa Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) & Y-o-Y Growth (%), 2022–2028

Figure 120: South Africa Benign Prostatic Hyperplasia Prostate Treatment Market Attractiveness Analysis, By Treatment, 2022E

Figure 121: South Africa Benign Prostatic Hyperplasia Prostate Treatment Market Attractiveness Analysis, By Distribution Channel, 2022E

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

Hirschsprung Disease Treatment Market

Published : September 2017

Healthcare

Phototherapy Treatment Market

Published : January 2022

Healthcare

Cancer Supportive Care Products Market

Published : July 2020

Healthcare

Leukemia Therapeutics Treatment Market

Published : February 2022

Google translate

Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market